

Improving Outcomes in Patients at Risk for Venous Thromboembolism Following Total Knee and Total Hip Replacement: Implications for Managed Care

The information presented in this supplement to *The American Journal of Managed Care* is based upon the conclusions and insights derived from a roundtable discussion, which identified means of overcoming barriers to improved outcomes for patients who have undergone surgery for total knee replacement (TKR) or total hip replacement (THR), and who are, consequently, at risk for venous thromboembolism (VTE). The diversity of the assembled healthcare professionals allowed for a wide-ranging discussion of clinical, institutional, and systemic approaches.

The roundtable and this publication were funded by Janssen Pharmaceuticals, Inc.; which included honoraria paid to the faculty members.

■ Faculty

Robert P. Navarro, PharmD (Moderator)

Clinical Professor
University of Florida—College of Pharmacy
Gainesville, Florida

James E. Barr, MD

Medical Director
Central Jersey Physician Network
Flemington, New Jersey

Karen Faubus, RN, BSN

Director
Clinical Pharmacy Services
Spur, Texas

Aman D. Sabharwal, MD, CPHM

Quality & Safety, and Revenue Cycle Management
Jackson Health System
Assistant Professor of Clinical Medicine
Florida International University College of Medicine
Fort Lauderdale, Florida

Electa Stern, PharmD

Clinical Supervisor, Pharmacy
Sharp Grossmont Hospital
La Mesa, California

Kevin Unger, MBA/MSHA, CHE

President and CEO
Poudre Valley Hospital
Fort Collins, Colorado

■ Faculty Disclosures

These faculty members have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:

James E. Barr, MD

Consultant:
Johnson & Johnson

Karen Faubus, RN, BSN

Advisory board/consultant/honoraria:
Janssen Pharmaceuticals, Inc

Aman D. Sabharwal, MD, CPHM

Advisory board/consultant:
Janssen Pharmaceuticals, Inc

Electa Stern, PharmD

Advisory board/consultant:
Boehringer Ingelheim

Kevin Unger, MBA/MSHA, CHE

Advisory board/honoraria:
Janssen Pharmaceuticals, Inc

The following participant has nothing to disclose relevant to the content of this supplement:

Robert P. Navarro, PharmD

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

Improving Outcomes in Patients at Risk for Venous Thromboembolism Following Total Knee and Total Hip Replacement: Implications for Managed Care

This supplement was supported by **Janssen Pharmaceuticals, Inc.**

• • •

The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.